Table 3.

Pharmacokinetic Properties of Injectable TU Formulations

	FDA Approval	PharmacoKinetics	Time to Tmax	Bioavailability in AUC0-tlast (ng/h/L)	Metabolism	Starting Dose	Titration	Special Precautions	Significant Adverse Effects
Aveed	Yes; March 2014	Ester bond is cleaved to release testosterone + inactive undecanoate; testosterone is then broken down to biologically active dihydrotestosterone (DHT) by 5a reductase	4 days	21,385	Beta oxidation	3 mL (750 mg) injected IM; then 4 weeks; then every 10 weeks	No titration	None	Acne, injection site reaction, pulmonary microembolism
Nebido	No		7 days	4051		4 mL (1000 mg) injected IM	No titration	None